KR20220046586A - 선택적 에스트로겐 수용체 분해제 - Google Patents

선택적 에스트로겐 수용체 분해제 Download PDF

Info

Publication number
KR20220046586A
KR20220046586A KR1020227005904A KR20227005904A KR20220046586A KR 20220046586 A KR20220046586 A KR 20220046586A KR 1020227005904 A KR1020227005904 A KR 1020227005904A KR 20227005904 A KR20227005904 A KR 20227005904A KR 20220046586 A KR20220046586 A KR 20220046586A
Authority
KR
South Korea
Prior art keywords
compound
formula
cancer
less
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227005904A
Other languages
English (en)
Korean (ko)
Inventor
란잔 쿠마르 팔
비스와짓 사만타
자야라즈 딜립바이 아라디
산딥 판카즈쿠르마 파닥
카우쉭 단지바이 프라자파티
바베시 모한바이 팬챌
트리나다 라오 치투리
Original Assignee
썬 파마 어드밴스트 리서치 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 썬 파마 어드밴스트 리서치 컴패니 리미티드 filed Critical 썬 파마 어드밴스트 리서치 컴패니 리미티드
Publication of KR20220046586A publication Critical patent/KR20220046586A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227005904A 2019-07-22 2020-07-22 선택적 에스트로겐 수용체 분해제 Ceased KR20220046586A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
KR20220046586A true KR20220046586A (ko) 2022-04-14

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227005904A Ceased KR20220046586A (ko) 2019-07-22 2020-07-22 선택적 에스트로겐 수용체 분해제

Country Status (15)

Country Link
US (2) US11014915B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003525A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541938A (cg-RX-API-DMAC7.html)
KR (1) KR20220046586A (cg-RX-API-DMAC7.html)
CN (1) CN114302879A (cg-RX-API-DMAC7.html)
AU (1) AU2020317099A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001285A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148592A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000156A1 (cg-RX-API-DMAC7.html)
IL (1) IL290036A (cg-RX-API-DMAC7.html)
MX (1) MX2022001013A (cg-RX-API-DMAC7.html)
PE (1) PE20221588A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014386A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201157B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) * 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
US12391667B2 (en) 2019-07-22 2025-08-19 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
BR112015030595A2 (pt) * 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
CN107406433A (zh) * 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
US10865199B2 (en) * 2015-10-27 2020-12-15 Sun Pharma Advanced Research Company Limited Heterocyclic antiestrogens
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Also Published As

Publication number Publication date
ZA202201157B (en) 2023-07-26
JP2022541938A (ja) 2022-09-28
CA3148592A1 (en) 2021-01-28
BR112022001285A2 (pt) 2022-03-22
WO2021014386A1 (en) 2021-01-28
PE20221588A1 (es) 2022-10-10
MX2022001013A (es) 2022-02-22
US20210261534A1 (en) 2021-08-26
US20210024504A1 (en) 2021-01-28
IL290036A (en) 2022-03-01
CN114302879A (zh) 2022-04-08
AU2020317099A1 (en) 2022-02-24
PH12022550182A1 (en) 2022-11-14
US11014915B2 (en) 2021-05-25
EP4003525A1 (en) 2022-06-01
CL2022000156A1 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
US11014915B2 (en) Selective estrogen receptor degrader
US20240226073A9 (en) TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
US6441193B1 (en) Estrogen agonists/antagonists
US7696357B2 (en) Stable hydrate of a muscarinic receptor antagonist
CN1181077A (zh) 苯并吡喃类化合物及其使用方法
CA2695126A1 (en) Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
EP2911660B1 (en) Compositions and methods for treating estrogen-related medical disorders
JP2008214353A (ja) Peg化イオンチャネル調節化合物
US20250197420A1 (en) Macrocyclic compounds, compositions, and methods of using thereof
US20110200687A1 (en) Bifeprunox mesylate maintenance dose compositions and methods for using the same
EP2076258A2 (en) Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
WO2004031125A1 (ja) スピロ化合物、それを含有する医薬組成物及び該化合物の中間体
JP3294574B2 (ja) 光学的に純粋なアンドロゲンメディエーター
RU2855858C2 (ru) ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
US8569342B2 (en) Diastereomers of 4-aryloxy-3-hydroxypiperidines

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601